// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

Differences in Prognosis for Patients with Interstitial Pneumonia with Acute Exacerbation of Varying Etiologies

M. Kato - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Idiopathic pulmonary fibrosis

Cyclophosphamide

Up of Participants from Urban Areas in India

S. Singh - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

N/A

Prevalence and Distribution of Depressive Mood Disorders in the University of Utah Interstitial Lung Disease Patient Population

S. E. Smith - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

N/A

Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease

Cory Perugino - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases

Clive Kelly - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Responses to Pirfenidone Treatment in Patients with Idiopathic Pulmonary Fibrosis is Not Associated with Changes in Echocardiographic Parameters of Left Ventricular Structure and Function

Shehab AlAnsari - Heart Failure Society of America (HFSA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Periostin Is a Novel Biomarker for Sarcoidosis

T. Isshiki - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

Angiotensin II

Wnt5a/ROR2 Signaling Is Associated with Bronchial Development and Bronchiectasis in Patients

D. Wang - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Elaszym

Parenchymal Crosstalk Regulates Lung Fibrosis Through Bmpr2 and Ctgf Signaling

T. Yanagihara - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

Tacrolimus

Chest CT Analysis for Features of Fibrosis in Children with SpC Genetic Mutations

E. M. DeBoer - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Diagnostic Delays in Interstitial Lung Diseases (ILDs)

M. Wijsenbeek - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

N/A

Polarization Sensitive Optical Coherence Tomography for In Vivo Microscopic Detection of Pulmonary Fibrosis

L. P. Hariri - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Impact of Chest CT Quality on the Diagnosis of Usual Interstitial Pneumonia (UIP) Pattern: A Hub and Spoke Study

G. Sgalla - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Quantification of Integrin avb6in Fibrotic Interstitial Lung Disease with a Cystine Knot PET Tracer. A First in Human Study

J. J. Mooney - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Beneficial Interstitial Matrix Fibroblasts Are Lost with Age, a New Perspective on Idiopathic Pulmonary Fibrosis

A. T. Perl - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Occurring Within the IPF Lung

T. Adams - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Improving Advance Care Planning for People with IPF

M. Kalluri - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Idiopathic pulmonary fibrosis

N/A

Treatment with Antifibrotic Agents in Pleuroparenchymal Fibroelastosis with Usual Interstitial Pneumonia

K. Sugino - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Methadone hydrochloride

Evaluating the Role of Support Group Participation on Palliative Care Referral and Mortality in Idiopathic Pulmonary Fibrosis

R. H. Zou - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension

J. Behr - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

Pirfenidone

Copyright © 2026. QuantiNova All rights reserved